IBRANCE, or palbociclib, is a cancer therapy drug. The use of IBRANCE in combination with the hormonal therapy Femara (letrozole) or Faslodex (fulvestrant) is a popular treatment for breast cancer. IBRANCE palbociclib breast cancer treatments specifically help treat HER2-negative post-menopausal women when hormonal therapy did not work.
IBRANCE Palbociclib Breast Cancer Treatments
This treatment works by inhibiting the protein that is in control of cell division. This helps to stop cancer cells from spreading. If you have HER2-negative breast cancer, your doctor may prescribe IBRANCE as an oral pill in combination with either Femara or Faslodex. However, be sure to fully discuss IBRANCE palbociclib breast cancer treatments with your doctor before you start taking it.
In addition, remember to discuss which types of foods, medication, and supplements that you may not be allowed to have while you are taking IBRANCE. Some examples include avoiding the consumption of the herb St. John’s wort, pomegranates, grapefruit, or their juices while you are taking this medication.
Also, do not take any other medication that contains a CYP3A inducer. This is because it will decrease the effectiveness of IBRANCE. Types of CYP3A inducer medications include Rifamate (rifampin) and Carbatrol (carbamazepine).
Other precautions include pregnancy and breastfeeding details. If you plan to get pregnant or are pregnant, plan to breastfeed or are breastfeeding, you should not take Ibrance.
Side Effects of IBRANCE Palbociclib Breast Cancer Treatments
Common side effects of IBRANCE include:
- hair loss
- loss of appetite
- mouth sores
Serious side effects that may occur as a result of IBRANCE are infections, blood clots, or neutropenia, which is a low count of white blood cells.
Since IBRANCE palbociclib breast cancer treatments are usually in combination with either Femara or Faslodex, you should also be aware of the side effects that may occur as a result of these medications.
It is important to remember that IBRANCE is currently approved for women who are post-menopause.
Featured Image: DepositPhotos/[email protected]Posted on May 30, 2018